Tags

Type your tag names separated by a space and hit enter

An algal-derived DL-galactan hybrid is an efficient preventing agent for in vitro dengue virus infection.
Planta Med. 2007 Nov; 73(14):1464-8.PM

Abstract

The DL-galactan hybrid C2S-3, isolated from the red seaweed Cryptonemia crenulata (Halymeniaceae, Halymeniales), is a potent and selective inhibitor of the multiplication of diverse strains of DENV-2 in Vero cells with higher effectiveness than the reference polysaccharide heparin. The presence of the compound either only at virus adsorption or at virus internalization exerted a significant and dose-dependent inhibition in DENV-2 plaque number. The compound failed to inactivate DENV-2 directly by incubation of virus before cell infection as well as to induce a refractory state by cell pretreatment. Thus, the inhibitory effect was exclusively exerted through a blockade in virus multiplication during the infectious process. When the entry of DENV-2 particles into the cell is bypassed, as occurs in virus RNA transfection, the polysaccharide C2S-3 failed to block the completion of the multiplication cycle. Furthermore, the antiviral properties of C2S-3 are not correlated with anticoagulant activity.

Authors+Show Affiliations

Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17948168

Citation

Talarico, Laura B., et al. "An Algal-derived DL-galactan Hybrid Is an Efficient Preventing Agent for in Vitro Dengue Virus Infection." Planta Medica, vol. 73, no. 14, 2007, pp. 1464-8.
Talarico LB, Duarte ME, Zibetti RG, et al. An algal-derived DL-galactan hybrid is an efficient preventing agent for in vitro dengue virus infection. Planta Med. 2007;73(14):1464-8.
Talarico, L. B., Duarte, M. E., Zibetti, R. G., Noseda, M. D., & Damonte, E. B. (2007). An algal-derived DL-galactan hybrid is an efficient preventing agent for in vitro dengue virus infection. Planta Medica, 73(14), 1464-8.
Talarico LB, et al. An Algal-derived DL-galactan Hybrid Is an Efficient Preventing Agent for in Vitro Dengue Virus Infection. Planta Med. 2007;73(14):1464-8. PubMed PMID: 17948168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An algal-derived DL-galactan hybrid is an efficient preventing agent for in vitro dengue virus infection. AU - Talarico,Laura B, AU - Duarte,María E, AU - Zibetti,Rosiane G, AU - Noseda,Miguel D, AU - Damonte,Elsa B, Y1 - 2007/10/18/ PY - 2007/10/20/pubmed PY - 2008/2/29/medline PY - 2007/10/20/entrez SP - 1464 EP - 8 JF - Planta medica JO - Planta Med VL - 73 IS - 14 N2 - The DL-galactan hybrid C2S-3, isolated from the red seaweed Cryptonemia crenulata (Halymeniaceae, Halymeniales), is a potent and selective inhibitor of the multiplication of diverse strains of DENV-2 in Vero cells with higher effectiveness than the reference polysaccharide heparin. The presence of the compound either only at virus adsorption or at virus internalization exerted a significant and dose-dependent inhibition in DENV-2 plaque number. The compound failed to inactivate DENV-2 directly by incubation of virus before cell infection as well as to induce a refractory state by cell pretreatment. Thus, the inhibitory effect was exclusively exerted through a blockade in virus multiplication during the infectious process. When the entry of DENV-2 particles into the cell is bypassed, as occurs in virus RNA transfection, the polysaccharide C2S-3 failed to block the completion of the multiplication cycle. Furthermore, the antiviral properties of C2S-3 are not correlated with anticoagulant activity. SN - 0032-0943 UR - https://www.unboundmedicine.com/medline/citation/17948168/An_algal_derived_DL_galactan_hybrid_is_an_efficient_preventing_agent_for_in_vitro_dengue_virus_infection_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-990241 DB - PRIME DP - Unbound Medicine ER -